Alx Oncology Holdings Stock Today
| ALXO Stock | USD 15.74 0.34 2.11% |
Performance5 of 100
| Odds Of DistressLess than 22
|
Alx Oncology is selling at 15.74 as of the 19th of April 2024; that is -2.11 percent decrease since the beginning of the trading day. The stock's open price was 16.08. Alx Oncology has about a 22 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Alx Oncology Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of January 2024 and ending today, the 19th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of July 2020 | Category Healthcare | Classification Health Care |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company was founded in 2015 and is headquartered in South San Francisco, California. Alx Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 50.15 M outstanding shares of which 3.12 M shares are presently shorted by private and institutional investors with about 6.39 trading days to cover. More on Alx Oncology Holdings
Moving against Alx Stock
| 0.59 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.54 | MRKR | Marker Therapeutics | PairCorr |
| 0.44 | ZNTL | Zentalis PharmaceuticalsL Financial Report 8th of May 2024 | PairCorr |
| 0.43 | IMMP | Immutep Ltd ADR | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 9th of May 2024
Alx Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Alx Oncology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Alx Oncology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Director | Jason Lettmann | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Alx Oncology report their recommendations after researching Alx Oncology's financial statements, talking to executives and customers, or listening in on Alx Oncology's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Alx Oncology Holdings. The Alx consensus assessment is calculated by taking the average forecast from all of the analysts covering Alx Oncology. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from Alx Oncology's financial statements, Alx Oncology Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Alx Oncology Holdings is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alx Oncology's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Alx Oncology's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alx Oncology's financial leverage. It provides some insight into what part of Alx Oncology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alx Oncology Holdings (ALXO) is traded on NASDAQ Exchange in USA. It is located in 323 Allerton Avenue, South San Francisco, CA, United States, 94080 and employs 72 people. Alx Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 806.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alx Oncology's market, we take the total number of its shares issued and multiply it by Alx Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Alx Oncology Holdings conducts business under Biotechnology sector and is part of Health Care industry. The entity has 50.15 M outstanding shares of which 3.12 M shares are presently shorted by private and institutional investors with about 6.39 trading days to cover.
Alx Oncology Holdings currently holds about 313.37 M in cash with (130.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.69.
Check Alx Oncology Probability Of Bankruptcy
Ownership AllocationAlx Oncology Holdings retains a total of 50.15 Million outstanding shares. The majority of Alx Oncology Holdings outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alx Oncology Holdings to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alx Oncology. Please pay attention to any change in the institutional holdings of Alx Oncology Holdings as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Alx Ownership Details
Alx Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Alx Oncology jumping above the current price in 90 days from now is about 13.15%. The Alx Oncology Holdings probability density function shows the probability of Alx Oncology stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.0426. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Alx Oncology will likely underperform. Additionally, alx Oncology Holdings has an alpha of 0.1862, implying that it can generate a 0.19 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Alx Oncology to move above the current price in 90 days from now is about 13.15 (This Alx Oncology Holdings probability density function shows the probability of Alx Stock to fall within a particular range of prices over 90 days) .
Alx Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Alx Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alx Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alx Oncology's value.| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2023-12-31 | 585 K | |
| T. Rowe Price Associates, Inc. | 2023-12-31 | 543.2 K | |
| State Street Corporation | 2023-12-31 | 501.5 K | |
| Citadel Advisors Llc | 2023-09-30 | 425.2 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 413.8 K | |
| Amvescap Plc. | 2023-12-31 | 385.2 K | |
| Renaissance Technologies Corp | 2023-12-31 | 270.5 K | |
| Northern Trust Corp | 2023-12-31 | 243.8 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 208.2 K | |
| Venbio Partners Llc | 2023-12-31 | 9.7 M | |
| Fmr Inc | 2023-12-31 | 7.5 M |
Alx Oncology Historical Income Statement
Alx Oncology Holdings Income Statement is one of the three primary financial statements used for reporting Alx's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Alx Oncology Holdings revenue and expense. Alx Oncology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Alx Oncology's Income Tax Expense is very stable compared to the past year. As of the 19th of April 2024, Interest Income is likely to grow to about 11.2 M, while Tax Provision is likely to drop 0.00. View More FundamentalsAlx Stock Against Markets
Picking the right benchmark for Alx Oncology stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Alx Oncology stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Alx Oncology is critical whether you are bullish or bearish towards Alx Oncology Holdings at a given time. Please also check how Alx Oncology's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Alx Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stock Screener Now
Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
| All Next | Launch Module |
Alx Oncology Corporate Management
Elected by the shareholders, the Alx Oncology's board of directors comprises two types of representatives: Alx Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alx. The board's role is to monitor Alx Oncology's management team and ensure that shareholders' interests are well served. Alx Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alx Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lisa Sauer | Senior Assurance | Profile | |
| Peter MBA | Chief Officer | Profile | |
| Christopher JD | General Counsel | Profile | |
| Corey Goodman | Independent Chairman | Profile | |
| Shelly Pinto | Senior Officer | Profile | |
| Sue Naim | Senior Operations | Profile | |
| Michael Chang | Vice Operations | Profile |
How to buy Alx Stock?
Before investing in Alx Oncology, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Alx Oncology. To buy Alx Oncology stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Alx Oncology. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Alx Oncology stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Alx Oncology Holdings stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Alx Oncology Holdings stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Alx Oncology Holdings, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Alx Stock please use our How to Invest in Alx Oncology guide.
Already Invested in Alx Oncology Holdings?
The danger of trading Alx Oncology Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alx Oncology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alx Oncology. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alx Oncology Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Alx Stock analysis
When running Alx Oncology's price analysis, check to measure Alx Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alx Oncology is operating at the current time. Most of Alx Oncology's value examination focuses on studying past and present price action to predict the probability of Alx Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alx Oncology's price. Additionally, you may evaluate how the addition of Alx Oncology to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Alx Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.74) | Quarterly Revenue Growth (1.00) | Return On Assets (0.39) | Return On Equity (0.71) |
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.